Afford, what if I told you I expected it as such all along, would you believe me? Well I did. Why didn't I say something? Well let's see, when the company essentially gave the timeline of extending the Ph III trial an extra year, what did that do? Hmmm, answer: the shorts came out to play. So nope, I'm not going to hurt shareholders or patients by revealing things that I perceive to be reality, if I think it could unjustly hurt the stock price. And I'm certainly not going to hurt the clinical trial process giving shorts info to frenzy on. At the end of the day the stock price is important. The higher, the less dilution, the quicker all things goes. And if the technology works, which I believe it does, based on all the anecdotal evidence, then it's a disservice to shareholders for me to share my own timeline assumption that are only negatives while in the midst of a catalyst waiting period. But sure, you can call my views of corporate strategy conjecture. I will call it as clear as day.
Market Data 
Markets 
AI
